Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients A Randomized Clinical Trial

被引：140

作者：

Johnstone, Jennie ^{[1
]}

Meade, Maureen ^{[2
]}

Lauzier, Francois ^{[3
]}

Marshall, John ^{[1
]}

Duan, Erick ^{[2
]}

Dionne, Joanna ^{[2
]}

Arabi, Yaseen M. ^{[4
]}

Heels-Ansdell, Diane ^{[2
]}

Thabane, Lehana ^{[2
]}

Lamarche, Daphnee ^{[2
]}

Surette, Michael ^{[2
]}

Zytaruk, Nicole ^{[2
]}

Mehta, Sangeeta ^{[1
]}

Dodek, Peter ^{[5
]}

McIntyre, Lauralyn ^{[6
]}

English, Shane ^{[6
]}

Rochwerg, Bram ^{[2
]}

Karachi, Tim ^{[2
]}

Henderson, William ^{[5
]}

Wood, Gordon ^{[7
]}

Ovakim, Daniel ^{[7
]}

Herridge, Margaret ^{[1
]}

Granton, John ^{[1
]}

Wilcox, M. Elizabeth ^{[1
]}

Goffi, Alberto ^{[1
]}

Stelfox, Henry T. ^{[8
]}

Niven, Daniel ^{[8
]}

Muscedere, John ^{[9
]}

Lamontagne, Francois ^{[10
]}

D'Aragon, Frederick ^{[10
]}

St-Arnaud, Charles ^{[10
]}

Ball, Ian ^{[11
]}

Nagpal, Dave ^{[11
]}

Girard, Martin ^{[12
]}

Aslanian, Pierre ^{[12
]}

Charbonney, Emmanuel ^{[12
]}

Williamson, David ^{[12
]}

Sligl, Wendy ^{[13
]}

Friedrich, Jan ^{[1
]}

Adhikari, Neill K. ^{[1
]}

Marquis, Francois ^{[12
]}

Archambault, Patrick ^{[3
]}

Khwaja, Kosar ^{[14
]}

Kristof, Arnold ^{[14
]}

Kutsogiannis, James ^{[13
]}

Zarychanski, Ryan ^{[15
]}

Paunovic, Bojan ^{[15
]}

Reeve, Brenda ^{[2
]}

Lellouche, Francois ^{[3
]}

Hosek, Paul ^{[2
]}

机构：

[1] Univ Toronto, Toronto, ON, Canada

[2] McMaster Univ, Hamilton, ON, Canada

[3] Univ Laval, Quebec City, PQ, Canada

[4] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia

[5] Univ British Columbia, Vancouver, BC, Canada

[6] Univ Ottawa, Ottawa, ON, Canada

[7] Univ Victoria, Victoria, BC, Canada

[8] Univ Calgary, Calgary, AB, Canada

[9] Queens Univ, Kingston, ON, Canada

[10] Univ Sherbrooke, Sherbrooke, PQ, Canada

[11] Western Univ, London, ON, Canada

[12] Univ Montreal, Montreal, PQ, Canada

[13] Univ Alberta, Edmonton, AB, Canada

[14] McGill Univ, Montreal, PQ, Canada

[15] Univ Manitoba, Winnipeg, MB, Canada

[16] Dalhousie Univ, Halifax, NS, Canada

[17] Mayo Clin, Rochester, MN USA

[18] Mercy Hosp, St Louis, MO USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2021年 / 326卷 / 11期

关键词：

CLOSTRIDIUM-DIFFICILE INFECTION; ANTIBIOTIC-ASSOCIATED DIARRHEA; PREVENTION; MICROBIOME; INPATIENTS; DYSBIOSIS; SEPSIS; ADULTS; BLIND;

D O I：

10.1001/jama.2021.13355

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Question Does the probiotic Lactobacillus rhamnosus GG prevent ventilator-associated pneumonia (VAP) among critically ill patients? Findings In this randomized trial involving 2650 patients, no significant difference in VAP incidence was found among patients treated with probiotics compared with placebo (21.9% vs 21.3%, respectively; hazard ratio 1.03; 95% CI 0.87-1.22). Meaning These findings do not support the use of Lactobacillus rhamnosus GG for prevention of ventilator-associated pneumonia in critically ill patients requiring mechanical ventilation. Importance Growing interest in microbial dysbiosis during critical illness has raised questions about the therapeutic potential of microbiome modification with probiotics. Prior randomized trials in this population suggest that probiotics reduce infection, particularly ventilator-associated pneumonia (VAP), although probiotic-associated infections have also been reported. Objective To evaluate the effect of Lactobacillus rhamnosus GG on preventing VAP, additional infections, and other clinically important outcomes in the intensive care unit (ICU). Design, Setting, and Participants Randomized placebo-controlled trial in 44 ICUs in Canada, the United States, and Saudi Arabia enrolling adults predicted to require mechanical ventilation for at least 72 hours. A total of 2653 patients were enrolled from October 2013 to March 2019 (final follow-up, October 2020). Interventions Enteral L rhamnosus GG (1 x 10(10) colony-forming units) (n = 1321) or placebo (n = 1332) twice daily in the ICU. Main Outcomes and Measures The primary outcome was VAP determined by duplicate blinded central adjudication. Secondary outcomes were other ICU-acquired infections including Clostridioides difficile infection, diarrhea, antimicrobial use, ICU and hospital length of stay, and mortality. Results Among 2653 randomized patients (mean age, 59.8 years [SD], 16.5 years), 2650 (99.9%) completed the trial (mean age, 59.8 years [SD], 16.5 years; 1063 women [40.1%.] with a mean Acute Physiology and Chronic Health Evaluation II score of 22.0 (SD, 7.8) and received the study product for a median of 9 days (IQR, 5-15 days). VAP developed among 289 of 1318 patients (21.9%) receiving probiotics vs 284 of 1332 controls (21.3%; hazard ratio [HR], 1.03 (95% CI, 0.87-1.22; P = .73, absolute difference, 0.6%, 95% CI, -2.5% to 3.7%). None of the 20 prespecified secondary outcomes, including other ICU-acquired infections, diarrhea, antimicrobial use, mortality, or length of stay showed a significant difference. Fifteen patients (1.1%) receiving probiotics vs 1 (0.1%) in the control group experienced the adverse event of L rhamnosus in a sterile site or the sole or predominant organism in a nonsterile site (odds ratio, 14.02; 95% CI, 1.79-109.58; P < .001). Conclusions and Relevance Among critically ill patients requiring mechanical ventilation, administration of the probiotic L rhamnosus GG compared with placebo, resulted in no significant difference in the development of ventilator-associated pneumonia. These findings do not support the use of L rhamnosus GG in critically ill patients. This clinical trial assessed whether Lactobacillus rhamnosus GG compared with placebo reduces ventilator-associated pneumonia and other clinically important outcomes for a broad range of critically ill patients.

引用

页码：1024 / 1033

页数：10

共 39 条

[1] Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial [J].